Peter Thiel-backed biotech developer AbCellera Biologics, which partnered with Eli Lilly for its COVID-19 antibody drug, has filed for an initial public offering, reported Reuters. Vancouver, British Columbia-based AbCellera filed for an IPO of up to US$200 million, a placeholder amount that is expected to change. The company plans to trade its stock on the NASDAQ under the ticker symbol “ABCL”. The company earlier this year raised US$105 million in Series B financing led by OrbiMed and DCVC Bio.
Source: Reuters
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: